AGP Franklin LLC Buys New Holdings in Humana Inc. (NYSE:HUM)

AGP Franklin LLC acquired a new stake in Humana Inc. (NYSE:HUM) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,937 shares of the insurance provider’s stock, valued at approximately $1,506,000.

A number of other hedge funds also recently made changes to their positions in the business. FPC Investment Advisory Inc. acquired a new position in shares of Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana in the fourth quarter valued at $30,000. LFA Lugano Financial Advisors SA raised its position in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Humana during the 4th quarter worth about $33,000. Finally, Atwood & Palmer Inc. boosted its holdings in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HUM shares. Guggenheim initiated coverage on shares of Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price target on the stock. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a report on Monday, April 7th. Truist Financial upped their price objective on Humana from $290.00 to $325.00 and gave the company a “hold” rating in a report on Friday. Morgan Stanley dropped their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Finally, Barclays raised their price target on shares of Humana from $270.00 to $322.00 and gave the stock an “equal weight” rating in a research report on Friday. Seventeen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $288.60.

Humana Trading Down 3.7 %

Shares of HUM opened at $284.27 on Tuesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The firm has a market cap of $34.31 billion, a price-to-earnings ratio of 28.57, a PEG ratio of 2.05 and a beta of 0.62. The business’s fifty day moving average is $265.43 and its 200-day moving average is $270.11.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.25%. Humana’s dividend payout ratio is currently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.